Senexin B

• Description :

  Senexin B (SNX2-1-165; BCD-115) is a potent, highly water-soluble and bioavailable CDK8/19 inhibitor, with Kds of 140 nM for CDK8 and 80 nM for CDK19.

• Product Name Alternative :

  SNX2-1-165; BCD-115

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Senexin_B.html

• Purity :

  99.09

• Solubility :

  DMSO : 6 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL

• Smiles :

  N#CC1=CC2=C(NCCC3=CC=C4C=C(C(N5CCN(C)CC5)=O)C=CC4=C3)N=CN=C2C=C1

• Molecular Formula :

  C27H26N6O

• Molecular Weight :

  450.53

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Porter D, et al. Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19. Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA) : AACR; Cancer Res 2015;75 (1 Suppl) :Abstract nr PR08. doi:10.1158/1538-7445.CHTME14-PR08|[2]McDermott MS, et al. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget. 2017 Feb 21;8 (8) :12558-12575.|[3]CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer. US 9321737 B2

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  CDK19; CDK8

• CAS Number :

  [1449228-40-3]